Comparing Selank and DSIP
An anxiety score, a hormone measurement and a night’s sleep give different accounts of a response. Putting them alongside each other helps preserve the differences.
Molecules and study subjects
| Selank | DSIP | |
|---|---|---|
| Identity | Synthetic heptapeptide, a stabilized tuftsin analogue also called TP-7 | Nine-amino-acid peptide, also called emideltide |
| Human work here | Russian anxiety study and immune measurements in anxiety-asthenic disorders | Sleep pilot in six chronic insomniacs and ACTH experiment in men |
| Mechanistic work | GABA binding in rat brain membranes and enkephalin breakdown in human plasma in vitro | No identified specific receptor, gene or precursor in the critical review |
| A changing observation | Rat frontal-cortex gene counts differed at one and three hours | The human pilot found slight arousal before its sleep-promoting effect |
“Stronger peptide” is a question I can’t rescue from these rows: none supplies a direct contest. The anxiety report and the sleep pilot asked different questions in different people. Even the more developed Selank mechanism leaves important human pharmacology unresolved.
Sleepiness and anxiety
The Selank clinical report describes anxiety relief with mild activation and without sedation. The DSIP pilot describes better sleep without daytime sedation, but also an early period of slight arousal. Both are small human reports with limited replication.
Those accounts complicate the neat daytime/nighttime pairing sometimes suggested by the names. A report of reduced anxiety leaves the sleep question open, and a sleep result leaves next-day function as another measurement. I’d rather learn how the following morning went than assign the compounds slots in a daily timetable.
Combination experiments and unanswered interactions
A rat experiment combined Selank with diazepam and found the strongest reduction in anxiety-related behaviour among its tested conditions. That is the combination tested there. It gives no answer about Selank and DSIP together.
The Selank plasma enzyme finding concerns endogenous opioid peptides; DSIP’s proposed opioid-system involvement remains uncertain. Shared interest in stress or sleep supplies no assurance about interactions. The combination FAQ addresses that evidence gap without attaching a regimen to it.
Community accounts
Selank anecdotes commonly describe calm with clarity, alongside reports of little effect, drowsiness, nasal irritation and headache. DSIP accounts are more visibly split: many report nothing, while easier sleep and clear mornings appear beside delayed effects and grogginess. These are anecdotal reports rather than clinical evidence; differences in the stories cannot establish comparative effectiveness or safety.
I’m particularly unconvinced by precise response-rate estimates assembled from those accounts. Without a defined study population, the apparent proportion has no firm denominator.
Approval status and extended follow-up
Neither peptide has FDA or EMA approval. Selank’s anxiolytic registration is essentially limited to Russia. U.S. prescription access depends on a licensed provider’s assessment and decision, and compounded medicines are not FDA-approved. Research-only materials have no pharmaceutical assurance of identity, purity or sterility.
Long-term human safety is unknown for both; the Selank anxiety report and DSIP sleep pilot are short observations. Pregnancy, breastfeeding and significant medical conditions remain unstudied safety questions. The individual Selank and DSIP pages give the experimental detail behind this comparison.
Sporting rules
WADA does not specifically name Selank or DSIP on its Prohibited List; its S0 catch-all for non-approved substances may encompass DSIP. Sporting eligibility still depends on the current rules and the relevant sporting authority.